GlaxoSmithKline gave up all the rights for all indications to vercirnon after the drug candidate performed poorly in a Phase III trial, according to News-Medical report.
ChemoCentryx now owns the drug's rights, including for inflammatory bowel disease, thus ending the seven-year strategic alliance between the two companies. GSK initially paid $63.5 million to ChemoCentryx to study treatments for IBD.
Vercirnon failed to meet GSK's primary and secondary endpoint in the first of four Phase III trials; the drug neither brought an improved clinical response nor clinical remission.
More Articles on Gastroenterology:
"S" or "C" Corporation for Your Gastroenterology Practice: Maximize Tax Deductions by Using Both!
Colonoscopy Could Prevent 40% Colon Cancer Cases, Study Says
Gastro Florida Practice Names Mark O'Neill as CEO
ChemoCentryx now owns the drug's rights, including for inflammatory bowel disease, thus ending the seven-year strategic alliance between the two companies. GSK initially paid $63.5 million to ChemoCentryx to study treatments for IBD.
Vercirnon failed to meet GSK's primary and secondary endpoint in the first of four Phase III trials; the drug neither brought an improved clinical response nor clinical remission.
More Articles on Gastroenterology:
"S" or "C" Corporation for Your Gastroenterology Practice: Maximize Tax Deductions by Using Both!
Colonoscopy Could Prevent 40% Colon Cancer Cases, Study Says
Gastro Florida Practice Names Mark O'Neill as CEO